Clinical Takeaways & Summary
- Continuous glucose monitors demonstrate an immediate 25-35% flattening of postprandial glucose peaks within Week 1.
- Circulating BHB levels rise between 0.3 and 0.8 mmol/L, supplying non-glycemic fuel to brain and muscle tissue.
- Long-term adherence over 90-180 days supports healthy baseline fasting insulin and visceral adipose mobilization.
1. Continuous Glucose Monitoring (CGM) in Weeks 1 – 2
Patients utilizing continuous interstitial glucose monitors (Dexcom or Freestyle Libre) observe measurable adaptations within the first 7 to 14 days of {PRODUCT_NAME} administration. Following a standard carbohydrate meal, the peak postprandial glucose excursion is reduced from an average baseline of 165 mg/dL down to 125–135 mg/dL.
More significantly, the “area under the curve” (AUC) is smoothed, preventing the sharp post-meal drop below 70 mg/dL that triggers reactive hypoglycemia, lethargy, and sugar cravings.
2. Ketonemia & Satiety Hormone Shifts in Weeks 3 – 6
By Weeks 3 through 6, exogenous BHB mineral salts induce mild nutritional ketonemia (0.4 to 0.7 mmol/L). In this physiological window:
- Fasting serum ghrelin levels decrease, reducing spontaneous between-meal appetite.
- Skeletal muscle mitochondria upregulate acetoacetate-CoA ligase, increasing lipid oxidation efficiency during physical exertion.
- Daytime cognitive focus stabilizes as cerebral neurons utilize circulating BHB as an alternative energy substrate.
3. Hepatic Insulin Sensitivity & Lipid Profiles at Day 90+
At the 90 to 180-day mark, consistent gastric transit pacing and reduced hyperinsulinemic episodes translate into measurable systemic laboratory endpoints: stabilized fasting blood glucose, healthy triglyceride-to-HDL ratios, and progressive reductions in visceral adipose storage.
Claim Verified Batch Allocation
Secure factory-direct manufacturer pricing starting at $39/unit with free domestic priority shipping.
Select Dispensary Supply Tier →